Header Logo

Connection

Matthew Meriggioli to Myasthenia Gravis, Autoimmune, Experimental

This is a "connection" page, showing publications Matthew Meriggioli has written about Myasthenia Gravis, Autoimmune, Experimental.
  1. Recombinant IgG2a Fc (M045) multimers effectively suppress experimental autoimmune myasthenia gravis. J Autoimmun. 2014 Aug; 52:64-73.
    View in: PubMed
    Score: 0.447
  2. GM-CSF-induced regulatory T cells selectively inhibit anti-acetylcholine receptor-specific immune responses in experimental myasthenia gravis. J Neuroimmunol. 2011 Dec 15; 240-241:65-73.
    View in: PubMed
    Score: 0.386
  3. Acetylcholine receptor-alpha subunit expression in myasthenia gravis: a role for the autoantigen in pathogenesis? Muscle Nerve. 2009 Aug; 40(2):279-86.
    View in: PubMed
    Score: 0.329
  4. Regulatory T cells induced by GM-CSF suppress ongoing experimental myasthenia gravis. Clin Immunol. 2008 Aug; 128(2):172-80.
    View in: PubMed
    Score: 0.303
  5. Strategies for treating autoimmunity: novel insights from experimental myasthenia gravis. Ann N Y Acad Sci. 2008; 1132:276-82.
    View in: PubMed
    Score: 0.295
  6. Suppression of experimental autoimmune myasthenia gravis by granulocyte-macrophage colony-stimulating factor is associated with an expansion of FoxP3+ regulatory T cells. J Immunol. 2006 Oct 15; 177(8):5296-306.
    View in: PubMed
    Score: 0.271
  7. Predictive value of serum anti-C1q antibody levels in experimental autoimmune myasthenia gravis. Neuromuscul Disord. 2006 Feb; 16(2):137-43.
    View in: PubMed
    Score: 0.064
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.